Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8897 - 8904 of 11617 results
Recent Federal Appellate Decisions Acknowledge Limits on Employer’s Obligation to Engage in ADA Interactive Process
July 7, 2015| Blog| Viewpoint
Divestiture Offer Fails to Save Merger Where FTC Wins on Market Definition Based on Customer Type
July 7, 2015| Alert| Viewpoint
Please Check Out Our New Class Action Recovery for Mutual Funds Blog
July 7, 2015| Blog| Viewpoint
Government’s Objections to Non-Intervened FCA Settlement Are Unreasonable – Now What?
July 7, 2015| Blog| Viewpoint
Uncertainty overshadows changes to EB-5 program
July 6, 2015| Blog| Viewpoint
Uncertain Future for Non-Compete Agreements in Massachusetts: Legislators Seek Compromise
July 6, 2015| Blog| Viewpoint
The Impact of King v. Burwell on "Applicable Large Employers"
July 6, 2015| Blog| Viewpoint
ITC Sheds Light on Economic Prong of Domestic Industry Under Subsection 337(a)(3)(C) and Issues General Exclusion Order
July 6, 2015| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.